Meningioma Recurrence Score
Variability in standard-of-care classifications precludes accurate predictions of early tumor recurrence for individual patients with meningioma, limiting the appropriate selection of patients who would benefit from adjuvant radiotherapy to delay recurrence.
Using the DNA methylation profiles of meningiomas across multiple institutions combined with pertinent clinical parameters (WHO grade and extent of resection), Nassiri et al. (2019, Neuro-Oncology) developed a clinical nomogram able to predict 5-year recurrence risk of meningiomas with greater discrimination and reliability than clinical factors or tumour methylome alone. Click here to access the Meningioma Methylation Nomogram website to upload your data and obtain a recurrence probability score.”
